Drug dis

Multidrug resistance in Cancer: Stratagem view and current challanges

  • Chair(s):

    Prof. Chiara Riganti,
    Associate professor, MD,Department of Oncology, Torino, Italy ,

    Prof. Javier De Las Rivas
    Full Professor, PhD,Cancer Research Center, University of Salamanca, Salamanca, Spain

  • Session description:

    Dissecting the MDR resistant phenotypes: new molecular circuitries, new therapeutic targets
    Professor Chiara Riganti
    Associate professor, MD, Department of Oncology, Torino, Italy

    Computational biology and OMICS data mining in MDR: a matter of networking
    Professor Javier De Las Rivas
    Full Professor, PhD, Cancer Research Center, University of Salamanca, Salamanca, Spain

    Biological and pharmacological underpinnings of therapeutic resistance in pancreatic cancer
    Professor Elisa Giovannetti
    Laboratory of Medical Oncology, Medical University of Amsterdam, The Netherlands

    The help of pharmaceutical nanotechnology in counteracting MDR
    Professor Elise Lepeltier
    Associate professor, PhD, University of Angers/INSERM 066 CNRS 6021, Angers, France

    Efficacy versus safety: what is most important in MDR reversing agents?
    Dr Yordan Yordanov
    Research associate, Faculty of Pharmacy, Medical University Sofia, Sofia, Bulgaria

    Between bedside and bench: how the clinical oncologist deals with MDR tumours
    Dr Elisabeth Pérez-Ruiz
    MD, Oncology Unit, Hospital Costa del Sol, Malaga, Spain

  • 00

    days

  • 00

    hours

  • 00

    minutes

  • 00

    seconds

Tags:

Date

04 Jul 2023

Time

4:05 pm - 5:50 pm

Speakers

Leave A Comment